Brígida R. Pinho

senior researcher

DL 57 Transitory Norm contract (since 2018)
Ciência Vitae

Recent publications

  • Pinho, BR; Duarte, AI; Canas, PM; Moreira, PI; Murphy, MP; Oliveira, JMA. 2020. The interplay between redox signalling and proteostasis in neurodegeneration: In vivo effects of a mitochondria-targeted antioxidant in Huntington's disease mice. FREE RADICAL BIOLOGY AND MEDICINE, 146, DOI: 10.1016/j.freeradbiomed.2019.11.021
  • Pinho, BR; Reis, SD; Hartley, RC; Murphy, MP; Oliveira, JMA. 2019. Mitochondrial superoxide generation induces a parkinsonian phenotype in zebrafish and huntingtin aggregation in human cells. FREE RADICAL BIOLOGY AND MEDICINE, 130, DOI: 10.1016/j.freeradbiomed.2018.10.446
  • Soares, TR; Reis, SD; Pinho, BR; Duchen, MR; Oliveira, JMA. 2019. Targeting the proteostasis network in Huntington's disease. AGEING RESEARCH REVIEWS, 49, DOI: 10.1016/j.arr.2018.11.006
  • Reis, SD; Pinho, BR; Oliveira, JMA. 2017. Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders. MOLECULAR NEUROBIOLOGY, 54, DOI: 10.1007/s12035-016-0120-z
  • Pinho, BR; Reis, SD; Guedes-Dias, P; Leitao-Rocha, A; Quintas, C; Valentao, P; Andrade, PB; Santos, MM; Oliveira, JMA. 2016. Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: Therapeutic implications for Parkinson's disease. PHARMACOLOGICAL RESEARCH, 103, DOI: 10.1016/j.phrs.2015.11.024
  • Pinho, BR; Santos, MM; Fonseca-Silva, A; Valentao, P; Andrade, PB; Oliveira, JMA. 2013. How mitochondrial dysfunction affects zebrafish development and cardiovascular function: an in vivo model for testing mitochondria-targeted drugs. BRITISH JOURNAL OF PHARMACOLOGY, 169, DOI: 10.1111/bph.12186